Evaluation of anticancer activity and mechanism of action of Myricetin on HeLa, T47D, and Vero cells: Comparative analysis with cisplatin and doxorubicin

Milliana, Alvi ORCID: https://orcid.org/0000-0003-1010-3591, Sari, Riza Ambar, Miranda, Shella Al and Mutiah, Roihatul ORCID: https://orcid.org/0000-0002-8196-9029 (2025) Evaluation of anticancer activity and mechanism of action of Myricetin on HeLa, T47D, and Vero cells: Comparative analysis with cisplatin and doxorubicin. Biomedical and Pharmacology Journal, 18 (1). pp. 835-847. ISSN 2456-2610

Text 23588.pdf - Published Version Available under License Creative Commons Attribution. Download (863kB)

Abstract

Cervical and breast cancers are two of the most common cancer affecting women. In Indonesia, there are 65,858 cases of breast cancer and 36,633 cases of cervical cancer have been recorded. Chemotherapy, using agents such as cisplatin and doxorubicin, is one of the main cancer therapies and works by targeting cancer cells. However, this therapy lacks selectivity and damages normal cells, leading to adverse side effects. An alternative chemopreventive treatment is Myricetin, a compound predicted to potentially target VEGF, a critical factor in angiogenesis, making it a promising anticancer agent. This study aims to evaluate the safety of Myricetin on Vero cells (normal cells), assess its anticancer activity on T47D and HeLa cells, and predict its mechanism of action. The anticancer activity was evaluated using the Microculture Tetrazolium Technique (MTT) assay on HeLa, T47D, and Vero cells. VEGF receptors were identified through a Network Pharmacology approach. The study also involved the Molecular Docking of Myricetin, cisplatin, and doxorubicin compounds with the 5DXH receptor. The results showed that Myricetin exhibited high cytotoxic activity against HeLa and T47D cells, with IC50 values of 22.70 μg/mL and 51.43 μg/mL, respectively, while demonstrating significantly lower cytotoxicity against Vero cells, with a CC50 value of 1445.2 μg/mL. In comparison, the CC50 values for cisplatin and doxorubicin against Vero cells were 6.53 μg/mL and 13.76 μg/mL, respectively, indicating that Myricetin is considerably less toxic to normal cells. Myricetin's Selectivity Index (SI) was 63.64 for HeLa cells and 28.09 for T47D cells, demonstrating superior selectivity compared to cisplatin and doxorubicin. These findings suggest that Myricetin has promising anticancer potential with a better safety profile than conventional chemotherapeutic agents.

Item Type:	Journal Article
Keywords:	Cisplatin; Doxorubicin; HeLa cells; Myricetin compound; T47D cells; VEGF; Vero cells
Subjects:	11 MEDICAL AND HEALTH SCIENCES > 1101 Medical Biochemistry and Metabolomics 11 MEDICAL AND HEALTH SCIENCES > 1104 Complementary and Alternative Medicine 11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis
Divisions:	Faculty of Medical and Health Sciences > Department of Medical Education Faculty of Medical and Health Sciences > Department of Pharmacy
Depositing User:	Dr. M.Kes. Roihatul Muti'ah
Date Deposited:	30 Apr 2025 12:10

Downloads

Origin of downloads

Actions (login required)

View Item